What's at stake: Cervical cancer screening device company TruScreen has lifted a trading halt after making an administrative error when allotting shares under a recent fundraising.
Background: The company has raised just over $4m, $1m more than sought, after the board said six months ago that TruScreen might not survive without raising cash.
Key players: TruScreen, Tony Ho, NZ RegCo.
New Zealand cervical cancer screening device company TruScreen has lifted a trading halt on its shares after admitting it made an administrative error when allotting shares for its share purchase plan.
NZX regulatory arm NZ RegCo put TruScreen’s shares into a trading halt on Wednesday morning
Sign up to get the latest stories and insights delivered to your inbox – free, every day.
Key points
What's at stake: Cervical cancer screening device company TruScreen has lifted a trading halt after making an administrative error when allotting shares under a recent fundraising.
Background: The company has raised just over $4m, $1m more than sought, after the board said six months ago that TruScreen might not survive without raising cash.
